Pothier says social media and telehealth pulled GLP-1s partly out of doctors' hands, pushing Novo and Lilly to rethink launches. Novo CEO Mike Doustdar weighs in too.
Recap by typeshit. Full story at Fierce Pharma.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
The investor piece cites retatrutide's 28.3% mean weight loss in an 80-week Phase 3 study and Lilly's push into combo and maintenance dosing.
As more people get weight loss drugs through telehealth, the pharmacies making compounded versions are drawing scrutiny. TIME looks at what buyers should know.
Loading…